Find Funding Opportunities

The purpose of this Notice is to inform the community that the National Institute of Neurological Disorders and Stroke (NINDS) intends to publish a Limited Competition Funding Opportunity Announcement (FOA) that will solicit an application for the Stroke Preclinical Assessment Network (SPAN) Coordinating Center. SPAN supports late-stage preclinical efficacy studies of putative cerebroprotectants to be given prior to or at the time of reperfusion in experimental stroke models. Parallel testing of the most promising interventions in a network structure will help to determine if an intervention can improve outcome as compared to reperfusion alone and/or extend the therapeutic window for reperfusion, with the overall goal of guiding the selection of the most promising agent(s) to transition to future Phase II clinical trials (to be conducted through StrokeNet). SPAN will consist of one Coordinating Center (CC), several testing sites, as well as intervention contributors. This infrastructure is expected to test multiple interventions in animal models of transient cerebral ischemia.

The purpose of this notice is to clarify the Award Budget for RFA-NS-22-009.

The National Institute of Neurological Disorders and Stroke (NINDS) will be hosting a pre-application technical assistancewebinar on October 27, 2021 from 1PM 2PM (Eastern Time) for all potential applicants interested in the following Funding Opportunity Announcement (FOA): RFA-NS-22-002 HEAL Initiative: Advancing Health Equity in Pain Management (R61/R33 Clinical Trial Required) This FOA aims to accelerate development, testing and implementation of evidence-based interventionsthat are culturally and linguistically appropriate for NIH-designated populations that experience health disparities (HDPs) in the United Statesto mitigate disparities in provision of care and treatment decisions, reduce susceptibility to chronic pain and improve patient outcomes. NIH program and review staff will ?provide an overview of the RFA, including objectives, application instructions and review criteria and will be available to answer questions. Potential applicants must register for the webinar using the link below. Following the webinar, a recording of the webinar, frequently asked questions (FAQs), and additional information may be found here: https://heal.nih.gov/news/events We request that participants carefully review the funding opportunities and the FAQs for this initiative prior to submitting a question for the webinar. Participation in the webinar is optional and is not required for the submission of an application.

The purpose of this Notice is to inform the community that the National Institute of Neurological Disorders and Stroke (NINDS) intends to publish a Funding Opportunity Announcement (FOA) that will solicit applications for Stroke Preclinical Assessment Network (SPAN) Interventions. SPAN supports late-stage preclinical efficacy studies of putative cerebroprotectants to be given prior to or at the time of reperfusion in experimental stroke models. Parallel testing of the most promising interventions in a network structure will help to determine if an intervention can improve outcome as compared to reperfusion alone and/or extend the therapeutic window for reperfusion, with the overall end goal of guiding the selection of the most promising agent(s) to transition to future Phase II clinical trials (to be conducted through StrokeNet). SPAN will consist of one Coordinating Center (CC), several testing laboratories, and intervention contributors. This infrastructure is expected to test multiple interventions in animal models of transient cerebral ischemia.

The purpose of this Notice is to inform the community that the National Institute of Neurological Disorders and Stroke (NINDS) intends to publish a Funding Opportunity Announcement (FOA) that will solicit applications for the Stroke Preclinical Assessment Network (SPAN) Testing Laboratories. SPAN supports late-stage preclinical efficacy studies of putative cerebroprotectants to be given prior to or at the time of reperfusion in experimental stroke models. Parallel testing of the most promising interventions in a network structure will help to determine if an intervention can improve outcome as compared to reperfusion alone and/or extend the therapeutic window for reperfusion, with the overall end goal of guiding the selection of the most promising agent(s) to transition to future Phase II clinical trials (to be conducted through StrokeNet). SPAN will consist of one Coordinating Center (CC), several testing laboratories, and intervention contributors. This infrastructure is expected to test multiple interventions in animal models of transient cerebral ischemia.

The purpose of this Notice is to inform the community that the National Institute of Neurological Disorders and Stroke (NINDS) intends to publish a Funding Opportunity Announcement (FOA) that will solicit applications for the Stroke Preclinical Assessment Network (SPAN)- Interventions from Small Businesses. SPAN supports late-stage preclinical efficacy studies of putative cerebroprotectants to be given prior to or at the time of reperfusion in experimental stroke models. Parallel testing of the most promising interventions in a network structure will help to determine if an intervention can improve outcome as compared to reperfusion alone and/or extend the therapeutic window for reperfusion, with the overall end goal of guiding the selection of the most promising agent(s) to transition to future Phase II clinical trials (to be conducted through StrokeNet). SPAN will consist of one Coordinating Center (CC), several testing laboratories, and intervention contributors. This infrastructure is expected to test multiple interventions in animal models of transient cerebral ischemia.

NIDA, with other NIH Blueprint for Neuroscience Research Institutes and Centers (ICs), intends to reissue initiative RFA-DA-16-009. The program is designed to either establish new research training programs or to support the continuation of meritorious existing training programs in computational neuroscience and behavior and for undergraduate and predoctoral level students. This Notice is being provided to allow potential applicants sufficient time to develop responsive projects. The overall objectives of the program have not changed, however, minor changes to improve the clarity and focus of the previous announcement are expected. The FOA is expected to be published in early 2022 with an expected application due date in Fall 2022.

The purpose of this time-sensitive Request for Information (RFI) is to seek input from scientists, clinicians, patients, families, caregivers, advocates, and the broader dementia community on the most important needs and promising opportunities for Alzheimer's disease-related dementias (ADRD) research. The information submitted in response to this RFI will be used by committees of scientists, clinicians, and other members of the public to revise and update the ADRD 2019 research recommendations.

The purpose of this Notice is to inform potential applicants an area of special interest to NHLBI, NINDS and NIA in research to understand mechanisms of vascular contributions to cognitive impairment and dementia (VCID) and to develop new approaches for the treatment of VCID.

NINDS is issuing this Notice of Special Interest to encourage the submission of applications focused on the development and validation of biomarkers for functional neurological disorders (FND). FND are a complex and heterogeneous group of neuropsychiatric syndromes. They are characterized by symptoms of altered voluntary motor or sensory function and frequently have comorbid medical, neurological, and psychiatric disorders. Although patients with FND represent the second commonest category of referrals to neurology outpatient clinics after headache, management is complex and requires interdisciplinary approaches. The high prevalence of FND, the disability caused by symptoms, high cost in healthcare utilization and loss of productivity points to an important opportunity for development of effective therapeutic interventions. This common, disabling, and costly group of conditions sits at the intersection of neurology and psychiatry. In the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM) the term functional is used as the primary descriptor in the term for this group of conditions, although the term conversion disorder is still accepted as an alternative expression that acknowledges unconscious processes in patients, though it emphasizes the implicit inference of causative psychological stressors, which are not always present or may not be readily identifiable. Diagnostic criteria for FND have been proposed, but are not universally accepted, and have varying rates of interrater reliability, depending on the symptom presentation (high for non-epileptic psychogenic seizures; poor for other FND). For this reason, diagnosis remains very challenging. Recent recommendations suggest that diagnosis should be based on positive clinical findings and supported, when necessary, by laboratory or ancillary investigation findings. Certain FND subtypes are more difficult to correctly diagnose than others.